GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » EPS without NRI

InnoCare Pharma (FRA:33C) EPS without NRI : €-0.06 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma EPS without NRI?

InnoCare Pharma's earnings per share without non-recurring items for the three months ended in Dec. 2023 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.06.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 6.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for InnoCare Pharma's EPS without NRI or its related term are showing as below:

FRA:33C' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -14   Med: 17.6   Max: 49
Current: 6

During the past 7 years, InnoCare Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 49.00% per year. The lowest was -14.00% per year. And the median was 17.60% per year.

FRA:33C's 3-Year EPS without NRI Growth Rate is ranked better than
50.69% of 1304 companies
in the Biotechnology industry
Industry Median: 5.45 vs FRA:33C: 6.00

InnoCare Pharma's EPS (Diluted) for the three months ended in Dec. 2023 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.06.

InnoCare Pharma's EPS (Basic) for the three months ended in Dec. 2023 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.06.


InnoCare Pharma EPS without NRI Historical Data

The historical data trend for InnoCare Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma EPS without NRI Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.22 -0.05 -0.01 -0.08 -0.05

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.03 -0.01 -0.01 -0.01

Competitive Comparison of InnoCare Pharma's EPS without NRI

For the Biotechnology subindustry, InnoCare Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's PE Ratio without NRI falls into.



InnoCare Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (FRA:33C) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


InnoCare Pharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines